Merck and Moderna Report Positive Phase 3 Results for Personalized mRNA Therapy in Melanoma
Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial for an individualized mRNA-based cancer therapy in melanoma.
A major development in personalized cancer immunotherapy has emerged from a Phase 3 clinical trial evaluating an individualized mRNA-based cancer therapy in melanoma.
Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial, reporting that the study met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS) in patients with completely resected stage IIB-IV melanoma.
The study evaluated intismeran autogene, also known as V940 or mRNA-4157, in combination with KEYTRUDA (pembrolizumab) compared with KEYTRUDA alone.
Read the original Merck and Moderna Phase 3 INTerpath-001 announcement
The companies described the findings as the first positive Phase 3 readout for an individualized neoantigen therapy and an mRNA-based cancer therapy.
Important: Intismeran autogene is an investigational therapy. The reported findings are topline results, and detailed clinical data are expected to be presented at a future international medical meeting.
What Did the INTerpath-001 Trial Show?
The randomized Phase 3 INTerpath-001 study was designed to determine whether adding intismeran autogene to pembrolizumab could improve outcomes compared with pembrolizumab alone after complete surgical removal of high-risk melanoma.
At a prespecified interim analysis, the combination demonstrated statistically significant and clinically meaningful improvements in both recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared with KEYTRUDA alone.
The trial will continue to evaluate additional outcomes, including overall survival (OS).
According to the companies, no new safety signals were observed, with the safety profile remaining consistent with previously reported studies of the combination.
Key Trial Facts
| Trial Feature | Details |
|---|---|
| Trial | INTerpath-001 |
| Phase | Phase 3 |
| Cancer type | Cutaneous melanoma |
| Disease stage | Stage IIB-IV |
| Treatment setting | Adjuvant treatment following complete resection |
| Participants | 1,137 |
| Experimental treatment | Intismeran autogene + KEYTRUDA |
| Comparator | KEYTRUDA alone |
| Primary endpoint | Recurrence-free survival |
| Key secondary endpoint | Distant metastasis-free survival |
| Additional outcomes | Overall survival, safety, tolerability and quality of life |
| Clinical trial ID | NCT05933577 |
The trial was designed as a global, randomized, double-blind, placebo- and active-comparator-controlled Phase 3 study.
Related clinical resource:
View INTerpath-001 (NCT05933577) on ClinicalTrials.gov
What Is Intismeran Autogene?
Intismeran autogene is an investigational individualized neoantigen therapy based on messenger RNA technology.
Unlike conventional cancer treatments that generally target a particular cancer-associated molecule across many patients, an individualized neoantigen therapy is designed around the specific mutations identified in an individual patient’s tumor.
The basic concept can be visualized as:
Tumor sample → genomic analysis → mutation identification → neoantigen selection → personalized mRNA therapy → immune activation
According to Merck and Moderna, each individualized therapy can encode multiple neoantigens selected according to the unique mutational characteristics of the patient’s tumor.
The objective is to stimulate the immune system—particularly T cells—to recognize and attack cancer cells carrying these tumor-associated neoantigens.
How Does an mRNA Cancer Vaccine Work?
The concept behind an individualized cancer vaccine combines several areas of modern biomedical science:
- Tumor genomic sequencing
- Bioinformatics
- Neoantigen discovery
- mRNA technology
- Cancer immunology
- T-cell biology
- Personalized medicine
After a patient’s tumor is analyzed, mutations that could generate tumor-specific neoantigens can be identified.
Selected neoantigens are then encoded into synthetic mRNA.
The mRNA provides instructions that allow cells to produce the relevant antigenic sequences, which can then be processed by the immune system.
The goal is to train or stimulate the immune system to recognize cancer cells carrying those specific tumor-associated targets.
Personalized rather than one-size-fits-all
The underlying concept is simple:
Every tumor has its own molecular fingerprint.
An individualized neoantigen therapy attempts to use that fingerprint to develop a treatment tailored to the patient’s cancer.
This is one reason personalized cancer vaccines are attracting increasing interest in oncology research.
Why Are RFS and DMFS Important?
Two important outcomes reported from INTerpath-001 are recurrence-free survival and distant metastasis-free survival.
What Is Recurrence-Free Survival?
Recurrence-free survival (RFS) measures the amount of time after treatment during which patients remain free from cancer recurrence or death.
In INTerpath-001, RFS was the primary endpoint.
For patients who have undergone complete surgical removal of high-risk melanoma, preventing or delaying recurrence is an important objective of adjuvant treatment.
What Is Distant Metastasis-Free Survival?
Distant metastasis-free survival (DMFS) focuses on the development of cancer that has spread to distant organs or death.
Because metastatic melanoma can be challenging to manage, preventing or delaying distant recurrence is an important goal of adjuvant therapy.
INTerpath-001 included DMFS as a key secondary endpoint and reported a statistically significant and clinically meaningful improvement with the combination treatment compared with KEYTRUDA alone.
Why Is the Phase 3 Result Important?
The significance of the announcement goes beyond melanoma.
Researchers have been investigating whether mRNA technology can be used beyond infectious-disease vaccines and adapted for cancer treatment.
The INTerpath-001 results provide an important Phase 3 clinical development milestone for an individualized mRNA-based cancer therapy.
The approach brings together several rapidly developing areas of oncology:
- mRNA therapeutics
- Tumor sequencing
- Computational biology
- Neoantigen prediction
- Cancer immunology
- T-cell activation
- Personalized medicine
Moderna and Merck are also investigating intismeran autogene in other cancer settings.
How Does This Build on Earlier Research?
The Phase 3 program builds on earlier findings from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study.
In 2026, Moderna and Merck presented five-year follow-up data for intismeran autogene combined with KEYTRUDA in patients with high-risk melanoma.
Moderna’s official ASCO 2026 update includes a video discussion of the five-year KEYNOTE-942 results:
Watch Moderna’s ASCO 2026 KEYNOTE-942 video update
The company’s presentation page also provides access to scientific material from the ASCO 2026 meeting:
View Moderna’s Scientific & Medical Meetings
These earlier findings helped support continued development of the individualized neoantigen strategy and the progression of the program into Phase 3.
What Happens Next?
The current announcement provides topline Phase 3 findings rather than the complete dataset.
Merck and Moderna have stated that detailed INTerpath-001 results will be presented at an upcoming international medical meeting.
The companies also plan to engage with regulatory authorities regarding potential regulatory submissions.
The trial will continue to evaluate additional endpoints, including overall survival.
This distinction is important:
A positive Phase 3 topline result does not automatically mean that an investigational therapy has received regulatory approval.
The complete dataset, longer-term follow-up and regulatory review will be important in determining the eventual clinical role of intismeran autogene.
The Future of Personalized Cancer Vaccines
The INTerpath-001 findings highlight a broader transformation taking place in oncology.
Cancer treatment is increasingly moving from a purely anatomical classification of disease toward a more detailed understanding of the molecular characteristics of individual tumors.
In the future, a personalized cancer treatment workflow could potentially look like:
Patient tumor → sequencing → computational analysis → neoantigen prediction → personalized treatment design → immune activation → response monitoring
This convergence of AI, genomics, mRNA biology and immunotherapy represents one of the most interesting areas of modern cancer research.
However, several important challenges remain, including:
- Manufacturing time
- Treatment cost
- Patient selection
- Neoantigen prediction
- Biomarker identification
- Durability of immune responses
- Long-term survival outcomes
- Regulatory requirements
INTerpath-001 Clinical Trial: Key Facts
INTerpath-001 is registered as NCT05933577 on ClinicalTrials.gov.
The study evaluates intismeran autogene plus pembrolizumab against pembrolizumab alone in patients with high-risk melanoma following complete surgical resection.
Check the official INTerpath-001 clinical trial record on ClinicalTrials.gov
Clinical trial registries are particularly useful for readers who want to examine study design, eligibility criteria, interventions and other official trial information.
Watch the Related Video
If you want a deeper look at the earlier clinical development of this personalized mRNA cancer therapy, Moderna has published an IR Insights video discussing the five-year Phase 2 KEYNOTE-942 results presented at ASCO 2026.
🎥 Related Video
Watch: Moderna’s ASCO 2026 KEYNOTE-942 5-Year Update
The video features Moderna leadership discussing the clinical findings and the ongoing development of intismeran autogene.
Related Scientific Resources
For readers who want to explore the science behind this development:
- Clinical Trial
INTerpath-001 — NCT05933577
Official clinical-trial information from ClinicalTrials.gov. - Scientific Presentation
Moderna Scientific & Medical Meetings
Includes Moderna’s ASCO 2026 scientific presentation on the five-year adjuvant melanoma update. - Original Company Announcement
Merck and Moderna: Phase 3 INTerpath-001 announcement
The primary source for the Phase 3 topline results discussed in this article.
Follow the Research
Readers can follow the companies’ official channels for future updates on mRNA technology, cancer research and clinical development.
For scientific and clinical updates, readers should prioritize official company announcements, peer-reviewed publications, clinical-trial registries and presentations from major oncology meetings.
What This Means for Oncology
The INTerpath-001 results represent an important development in the evolution of personalized cancer immunotherapy.
The combination of an individualized mRNA-based neoantigen therapy with KEYTRUDA has reported positive Phase 3 topline results for both recurrence-free survival and distant metastasis-free survival in patients with completely resected high-risk melanoma.
The next important steps will be the publication or presentation of detailed clinical data, continued follow-up—including overall survival—and regulatory review.
For oncology researchers and healthcare professionals, the development is particularly notable because it brings together:
mRNA therapeutics + tumor genomics + computational biology + neoantigens + immunotherapy
The results raise an important question for the future of oncology:
Could individualized cancer vaccines become a new component of precision immunotherapy?
The answer will depend on the complete Phase 3 dataset, longer-term outcomes, regulatory evaluation and ultimately how these therapies perform in routine clinical practice.
Frequently Asked Questions
What is intismeran autogene?
Intismeran autogene, also known as V940 or mRNA-4157, is an investigational individualized neoantigen therapy designed to stimulate an immune response against tumor-specific targets.
What cancer is being studied in INTerpath-001?
The Phase 3 INTerpath-001 study evaluates the therapy in patients with high-risk, completely resected stage IIB-IV melanoma.
What is an mRNA cancer vaccine?
An mRNA cancer vaccine is an investigational approach that uses messenger RNA to provide instructions associated with cancer-specific or tumor-associated antigens, with the goal of stimulating an immune response against cancer.
Is intismeran autogene approved?
The Phase 3 INTerpath-001 announcement reports topline clinical-trial results. Intismeran autogene remains an investigational therapy, and regulatory review is required before any potential approval.
What is the INTerpath-001 trial number?
The ClinicalTrials.gov identifier for INTerpath-001 is NCT05933577.
What is the difference between RFS and DMFS?
RFS measures the period during which patients remain free from recurrence or death, while DMFS specifically focuses on distant metastatic recurrence or death.
Medical Disclaimer
This article is intended for educational and research purposes only. It summarizes publicly available information about an investigational cancer therapy and should not be interpreted as medical advice, treatment guidance or a recommendation for any specific patient.
Intismeran autogene is an investigational therapy. Clinical-trial results and regulatory status may change as additional data become available. Patients should discuss melanoma treatment options with a qualified oncology professional.
Sources
This article is based primarily on the official Merck and Moderna announcement regarding the Phase 3 INTerpath-001 trial, the ClinicalTrials.gov trial record and Moderna’s publicly available scientific and ASCO 2026 materials.
Primary source:
Merck and Moderna — INTerpath-001 Phase 3 announcement
Clinical trial:
ClinicalTrials.gov — NCT05933577
Related video and clinical update:
Moderna — ASCO 2026 KEYNOTE-942 5-Year Update
Scientific presentation:
Moderna — Scientific & Medical Meetings
Educational content only. This material is written for healthcare professionals and students. It is not medical advice, and it must not be used for diagnosis or treatment decisions. Clinical decisions remain the responsibility of a qualified healthcare professional. Full disclaimer
Related resources
Discover how AI-powered clinical trial matching can help breast cancer patients and oncologists identify potentially relevant clinical trials faster—and understand its benefits and limitations.
A new AI model analyzes routine H&E pathology slides to predict TP53 mutations, RNA expression, tumor type and survival outcomes across 32 cancer types.
GenBio AI's AIDO Cell aims to simulate human cells from DNA and RNA to proteins and whole-cell behavior. Explore what virtual cells could mean for drug…